Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

November 29, 2018 Group News

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke

Amsterdam, The Netherlands – 29 November 2018
read more

Esperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease.

October 20, 2016 Group News

The Cell Factory develops therapy for Crohn’s disease.

Esperite’s business unit The Cell Factory, in collaboration with Women’s and Children’s Health Department of the University of Padua and the Padua University Hospital have started a translational project on extracellular vesicles (including exosomes) first in man use in treatment of Crohn’s disease perianal fistulas. Inflammatory bowel disease (IBD) affects approximately 0.5% of the western countries population and this number is rapidly increasing. There are over 0.5 million people in the US and over 1 million in Europe with Crohn’s disease, with over 10 new cases per 100.000 people every year. The annual cost of therapy exceeds 5 billion USD in the US only (CDC). Up to 50% of Crohn’s disease patients are affected with difficult to treat perianal fistulas, and 75% require surgery (CDC).

Zutphen, The Netherlands – 20 October 2016